FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Globulin topics
Immunoglobulin
Antibodies
Recombinant
Immunoglobulins
Polypeptide
Cancer Cell
Nucleic Acid
Immune Response
Monoclonal
Compatibility
Major Histocompatibility Complex
Histocompatibility
Prophylactic
Extracellular
Metastasis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Globulin patents



      
           
This page is updated frequently with new Globulin-related patent applications. Subscribe to the Globulin RSS feed to automatically get the update: related Globulin RSS feeds. RSS updates for this page: Globulin RSS RSS


Date/App# patent app List of recent Globulin-related patents
07/24/14
20140206019
 Fc-function assay patent thumbnailFc-function assay
The present invention discloses a method of assaying fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a f-s-l peptide-lipid construct. The f-s-l peptide construct comprises a functional group (f) that is a target antigen for a complement activating immunoglobulin, a spacer group (s) covalently linking f to l and a lipid group (l).
07/24/14
20140205607
 Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing patent thumbnailFocused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Antibody vrc01 represents a human immunoglobulin that neutralizes—˜90% of diverse hiv-1 isolates. To understand how such broadly neutralizing hiv-1 antibodies develop and recognize the viral envelope, we used x-ray crystallography and 454 pyrosequencing to characterize additional antibodies from hiv-1-infected individuals.
07/24/14
20140205597
 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains patent thumbnailTechniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given isv will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ada immunoassay). Such predictive assays could for example be used to test whether a given isv could have a tendency to give rise to such protein interference and/or such a signal; to select isv's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an isv will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an isv so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving isv's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an isv that remove or reduce its tendency to give rise to such protein interference or such a signal; isv's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved isv's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal..
07/24/14
20140205560
 Multimeric il-15 soluble fusion molecules and methods of making and using same patent thumbnailMultimeric il-15 soluble fusion molecules and methods of making and using same
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (il-15) polypeptide or a functional fragment thereof.
07/17/14
20140200331
 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof patent thumbnailEngineered immunoglobulin heavy chain-light chain pairs and uses thereof
The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the ch1 and/or cl domains, amino acid modifications in the vh and/or vl domains or a combination thereof.
07/17/14
20140200159
 Identifying antigen clusters for monitoring a global state of an immune system patent thumbnailIdentifying antigen clusters for monitoring a global state of an immune system
Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.. .
07/17/14
20140199316
 Methods of treating complications and disorders associated with g-csf administration patent thumbnailMethods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
07/17/14
20140199295
 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains patent thumbnailTechniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given isv will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ada immunoassay). Such predictive assays could for example be used to test whether a given isv could have a tendency to give rise to such protein interference and/or such a signal; to select isv's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an isv will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an isv so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving isv's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an isv that remove or reduce its tendency to give rise to such protein interference or such a signal; isv's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved isv's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal..
07/10/14
20140193838
 Method for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies patent thumbnailMethod for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies
A method for measuring the amount of sialic acid in immunoglobulin g and immunoglobulin g anti-ds dna antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin g in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin g.
07/10/14
20140193407
 Drug fusions and conjugates patent thumbnailDrug fusions and conjugates
The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and glp and/or exendin molecules.
07/10/14
20140193399
Anti-cd3 antibodies and methods of use thereof
The present invention is related to antibodies directed to the antigen cd3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to cd3.
07/10/14
20140193359
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
07/03/14
20140187753
Hetero-dimeric immunoglobulins
The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.. .
07/03/14
20140187519
Biomarkers for predicting major adverse events
Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin c..
07/03/14
20140186345
Method of administering an antibody
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month..
07/03/14
20140186293
Immunoglobulin-bound extracellular vesicles and uses thereof
Provided are methods of isolating igg-bound (e.g., igg-bound or protein g-recognized igg-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the igg (e.g., igg2 or protein g-recognized igg) is bound to an antigen present on the surface of the extracellular vesicle and the igg (e.g., igg2 or protein g-recognized igg) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle that contains one or more tumor antigens..
06/26/14
20140179898
Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent
A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.
06/26/14
20140179550
Immunoglobulin fc libraries
Methods and composition for the screening and isolation of aglycosylated antibody fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated fc domains that bind to fc receptors or preferentially bind to particular fc receptors are described.
06/26/14
20140179547
Methods for the generation of multispecific and multivalent antibodies
The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a kappa constant domain and the other of a lambda constant domain.
06/26/14
20140178916
Method of neonatal serological diagnosis
The present invention provides a method for determining the amino acid polymorphisms of heavy gamma chain of immunoglobulins g by a proteomic approach. This method distinguishes the immunoglobulins of the mother and those of the newborn in a blood sample obtained during the first months of the child's life.
06/26/14
20140178869
Detection of immunoglobulin light chain restriction by rna in situ hybridization
The invention provides a method for detecting immunoglobulin light chain restriction and clonality in b cells by obtaining a sample of b cells from a subject; conducting a duplex in situ hybridization assay on the sample using (i) at least one probe set which is designed to specifically hybridize to immunoglobulin kappa chain constant region (igkcr) rna; and (ii) at least one probe set which is designed to specifically hybridize to immunoglobulin lambda chain constant region (iglcr) rna; detecting signal associated with hybridized igkcr probe and signal associated with hybridized iglcr probe in a population of b cells in the sample; and determining a pattern of signal associated with hybridized igkcr probe and hybridized iglcr probe within individual cells in the b cell population, wherein the pattern of signal within individual cells indicates the presence or absence of light chain restriction and clonality of the b cells.. .
06/26/14
20140178390
Biological materials related to cxcr7
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting cxcr7 mediated tumour growth..
06/26/14
20140178364
Compositions and methods for targeting type 1 interferon producing cells
The present disclosure provides a method for treating lupus, sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (il-3rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p dcs) and basophils to which it binds.. .
06/26/14
20140178361
Method for polyclonal immunoglobulin g production by human b cells
This application relates to an in vitro method of producing a polyclonal igg preparation. The method comprises (i) placing a polyclonal b-cell population enriched in igg-secreting b cells in a culture medium; and (ii) culturing the polyclonal b-cell population under conditions enabling the production of the polyclonal igg preparation from the polyclonal b-cell population.
06/26/14
20140178294
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
06/19/14
20140171621
Galectin-immunoglobulin chimeric molecules
Described are galectin-1/ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.. .
06/19/14
20140170171
Targeted cytokine for treatment of musculoskeletal diseases
Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a tgf-beta associated with immunoglobulins (such as iggs) or functional portions thereof including fc portions, such as by non-covalent bonds.
06/19/14
20140170169
Blocking antibody for transplantation
A method can include administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient where the antibody is an immunoglobulin g subclass 4 antibody (g4). Various other examples of devices, assemblies, systems, methods, etc., are also disclosed..
06/19/14
20140170137
Therapeutic canine immunoglobulins and methods of using same
A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen.


Popular terms: [SEARCH]

Globulin topics: Immunoglobulin, Antibodies, Recombinant, Immunoglobulins, Polypeptide, Cancer Cell, Nucleic Acid, Immune Response, Monoclonal, Compatibility, Major Histocompatibility Complex, Histocompatibility, Prophylactic, Extracellular, Metastasis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Globulin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Globulin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2996

3835

74 - 0 - 79